Document:

EX-10.31

 Exhibit 10.31 

September 4, 2018 
 Jacqualyn
Fouse, Ph.D. 
 RE:     Separation Agreement and General Release 

Dear Jackie, 
 Your employment
with Dermavant Sciences, Inc. will be terminated effective September 4, 2018 (the “Termination Date”). This Separation Agreement and General Release (this “Agreement”) sets forth the terms and conditions under which
Dermavant Sciences, Inc. is offering you a bonus in exchange for you making and honoring certain commitments, including agreeing not to pursue legal action against the Company as described in Sections 6 and 7. 

PLEASE NOTE: THIS DOCUMENT HAS IMPORTANT LEGAL CONSEQUENCES TO YOU. YOU SHOULD CONSULT AN ATTORNEY OF YOUR CHOICE, AT YOUR EXPENSE, PRIOR
TO EXECUTING IT. 
  

	1.	 Parties To This Agreement 

This letter is a proposed agreement that Dermavant Sciences, Inc. is offering to you. In this document, references to
JACQUALYN FOUSE refer to “you” and DERMAVANT SCIENCES, INC. is referred to as “Dermavant” or the “Company.” Together, you and Dermavant are referred to as the “Parties.” 

 

	2.	 What You Will Receive Only If You Enter Into This Agreement. 

As long as you timely sign, date and return this Agreement (but in no case later than 21 days after presentation of
agreement), and you comply with this Agreement’s requirements, you will receive a bonus in an amount equal to your target annual performance bonus, prorated for the period from April 1, 2018 through September 4, 2018, which
shall be payable in a lump sum as soon as practicable following the effective date of this Agreement but no later than the payroll cycle immediately following the effective date. 

 

	3.	 W-2s. 

The Company will issue an IRS Form W-2 to you in connection with payments described in
Section 2. 
  

	4.	 How To Enter Into This Agreement. 

In order to enter into this Agreement, you must take the following steps: 

  
 1 

	 	•	 	 You must sign and date this Agreement. Signing and dating the Agreement is how you “Execute” the
Agreement. 

  

	 	•	 	 You must return the Executed Agreement to me before September 25, 2018, (unless such period is extended
in writing by the Company), but no earlier than the Termination Date. If I do not receive the signed and dated Agreement by that date, the offer will be deemed withdrawn, this Agreement will not take effect and you will not receive the bonus
described in Section 2. 

  

	 	•	 	 You must comply with the terms and conditions of this Agreement. 

 

	5.	 Your Acknowledgments. 

By entering into this Agreement, you are agreeing: 
  

	 	•	 	 The bonus amount in Section 2 is more than any amount or benefits that you are otherwise promised or
entitled to receive under any policy, plan, handbook or practice of the Company or any prior offer letter, agreement or understanding between the Company and you. 

 

	 	•	 	 After your employment ends, except as provided for in this Agreement (and without impacting any accrued vested
benefits under any applicable tax-qualified retirement or other benefit plans of the Company), you will no longer participate or accrue service credit of any kind in any employee benefits plan of the Company
or any of its affiliates. 

  

	 	•	 	 With respect to the stock options granted to you (the “Option Award”) pursuant to
Section 3.3(a) of your employment agreement with the Company dated July 1, 2017 (the “Employment Agreement”), (a) twenty- five percent (25%) of the Option Award vested on July 1, 2018; and (b) the remaining unvested
portion of your Option Award (including but not limited to the unvested portion of your Option Award that would otherwise vest on October 1, 2018) shall be forfeited as of the Termination Date, and you shall have no further rights with respect
thereto. In addition, all 66,845 restricted stock units granted to you pursuant to the Roivant Sciences Ltd. 2015 Restricted Stock Unit Plan will be forfeited as of the Termination Date. You also hereby acknowledge and agree that you will not be
entitled to receive any Anti-Dilution Grants (as defined in the Employment Agreement) and hereby waive any and all rights you may have with respect thereto. 

  

	 	•	 	 Your obligations under your signed Employment Agreement dated July 1, 2017, and the Employee Non-Disclosure, Inventions Assignment and Restrictive Covenant Agreement (“NDA”) between you and the Company, shall remain in full force and effect and you acknowledge and
re-affirm those obligations. 

  

	6.	 YOU ARE RELEASING AND WAIVING CLAIMS 

While it is very important that you read this entire Agreement carefully, it is especially important that you read
this Section carefully, because it lists important rights you are giving up if you decide to enter into this Agreement. 

  
 2 

 Who And What Does The Release Cover? 

What Are You Giving Up? It is the Company’s position that you have no legitimate basis for bringing a legal
action against it. You may agree or believe otherwise or simply not know. However, if you Execute this Agreement, you will, except for certain exceptions described in Section 8, give up your ability to bring a legal action against the Company
and others, including, but not limited to its affiliates. More specifically, by Executing this Agreement, you will give up any right you may have to bring various types of “Claims,” which means possible lawsuits, claims, demands and causes
of action of any kind (based on any legal or equitable theory, whether contractual, common-law, statutory, federal, state, local or otherwise), whether known or unknown, by reason of any act or omission up to
and including the date on which you Execute this Agreement. You are also giving up potential Claims arising under any contract or implied contract, including but not limited to your Employment Agreement or any handbook, tort law or public policy
having any bearing on your employment or the termination of your employment, such as Claims for wrongful discharge, discrimination, hostile work environment, breach of contract, tortious interference, harassment, bullying, infliction of emotional
distress, defamation, back pay, vacation pay, sick pay, wage, commission or bonus payment, equity grants, stock options, restricted stock option payments, payments under any bonus or incentive plan, attorneys’ fees, costs and future wage loss.
This Agreement includes a release of your right to assert a Claim of discrimination on the basis of age, sex, race, religion, national origin, marital status, sexual orientation, gender identity, gender expression, ancestry, parental status,
handicap, disability, military status, veteran status, harassment, retaliation or attainment of benefit plan rights. However, as described in Section 8, this Agreement does not and cannot prevent you from asserting your right to bring a claim
against the Company and Releasees, as defined below, before the Equal Employment Opportunity Commission or other agencies enforcing non-discrimination laws or the National Labor Relations Board. 

Whose Possible Claims Are You Giving Up? You are waiving Claims that you may otherwise be able to bring. You are
not only agreeing that you will not personally bring these Claims in the future, but that no one else will bring them in your place, such as your heirs and executors, and your dependents, legal representatives and assigns. Together, you and these
groups of individuals are referred to in the Agreement as “Releasors.” 
 Who Are You Releasing From Possible
Claims? You are not only waiving Claims that you and the Releasors may otherwise be able to bring against the Company, but also Claims that could be brought against “Releasees,” which means the Company and all of their past,
present and future: 
  

	 	•	 	 shareholders 

  

	 	•	 	 officers, directors, employees, attorneys and agents 

 

	 	•	 	 subsidiaries, divisions and affiliated and related entities 

 

	 	•	 	 employee benefit and pension plans or funds 

 

	 	•	 	 successors and assigns 

 

	 	•	 	 trustees, fiduciaries and administrators 

  
 3 

 Possible Claims You May Not Know. It is possible that you may
have a Claim that you do not know exists. By entering into this Agreement, you are giving up all Claims that you ever had including Claims arising out of your employment or the termination of your employment. Even if Claims exist that you do not
know about, you are giving them up. 
 What Types of Claims Are You Giving Up? In exchange for the bonus in
Section 2, you (on behalf of yourself and the Releasors) forever release and discharge the Company and all of the Releasees from any and all Claims including Claims arising under the following laws (including amendments to these laws): 

Federal Laws, such as: 
  

	 	•	 	 The Age Discrimination in Employment Act; 

 

	 	•	 	 The Older Workers Benefit Protection Act; 

 

	 	•	 	 Title VII of the Civil Rights of 1964; 

 

	 	•	 	 Sections 1981 through 1988 of Title 42 of the United States Code; 

 

	 	•	 	 The Civil Rights Act of 1991; 

 

	 	•	 	 The Equal Pay Act; 

  

	 	•	 	 The Americans with Disabilities Act; 

 

	 	•	 	 The Rehabilitation Act; 

 

	 	•	 	 The Employee Retirement Income Security Act; 

 

	 	•	 	 The Worker Adjustment and Retraining Notification Act; 

 

	 	•	 	 The National Labor Relations Act; 

 

	 	•	 	 The Fair Credit Reporting Act; 

 

	 	•	 	 The Occupational Safety and Health Act; 

 

	 	•	 	 The Uniformed Services Employment and Reemployment Act; 

 

	 	•	 	 The Employee Polygraph Protection Act; 

 

	 	•	 	 The Immigration Reform Control Act; 

 

	 	•	 	 The Family and Medical Leave Act; 

 

	 	•	 	 The Genetic Information Nondiscrimination Act; 

 

	 	•	 	 The Federal False Claims Act; 

 

	 	•	 	 The Patient Protection and Affordable Care Act; 

 

	 	•	 	 The Consolidated Omnibus Budget Reconciliation Act; and 

 

	 	•	 	 The Lilly Ledbetter Fair Pay Act. 

State and Municipal Laws, such as: 
  

	 	•	 	 The New York State Human Rights Law; the New York State Executive Law; the New York State Civil Rights Law;
the New York State Whistleblower Law; the New York State Legal Recreational Activities Law; the retaliation provisions of the New York State Workers’ Compensation Law; the New York Labor Law; the New York State Worker Adjustment and Retraining
Notification Act; the New York State False Claims Act; New York State Wage and Hour Laws; the New York State Equal Pay Law; the New York State Rights of Persons with Disabilities Law; the New York State Nondiscrimination Against Genetic Disorders
Law; the New York State Smokers’ Rights Law; the New York AIDS Testing Confidentiality Act; the New York Genetic Testing Confidentiality Law; the New York Discrimination by Employment Agencies Law; the New York Bone Marrow Leave Law; the New
York Adoptive Parents Child Care Leave Law; the New York City Human Rights Law; the New York City Administrative Code; the New York City Paid Sick Leave Law; and the New York City Charter; and 

  
 4 

	 	•	 	 The North Carolina Employment Practices Act; the Retaliatory Employment Discrimination Act; the Persons with
Disabilities Protection, Discrimination Against Persons with Sickle Cell Trait; Discrimination Based Upon Genetic Testing and Information; Discrimination Based Upon Use of Lawful Products; Discrimination Based Upon AIDS or HIV Status; Hazardous
Chemicals Right to Know Act; Jury Service Discrimination; Military Service Discrimination; and all of their respective implementing regulations; and 

  

	 	•	 	 The Massachusetts Fair Employment Practices Law; the Massachusetts Civil Rights Act; the Massachusetts Equal
Rights Act; the Minimum Fair Wage Act; the Massachusetts Plant Closing Law; the Massachusetts Equal Pay Act; the Massachusetts Parental Leave Act; the Massachusetts Sexual Harassment Statute; and all of their respective implementing regulations. By
signing this letter agreement, you are acknowledging that this waiver includes any future claims against the Company under Mass. Gen. Laws ch. 149, § 148 - the Massachusetts Wage Act. These claims include, but are not limited to, failure
to pay earned wages, failure to pay overtime, failure to pay earned commissions, failure to timely pay wages, failure to pay accrued vacation or holiday pay, failure to furnish appropriate pay stubs, claims for improper wage deductions, and claims
for failing to provide proper check-cashing facilities; and 

  

	 	•	 	 Any other applicable State or Municipal Law. 

You Are Giving Up Potential Remedies and Relief. You are waiving any relief that may be available to you (such as money damages,
equity grants, benefits, attorneys’ fees, and equitable relief such as reinstatement) under any of the waived Claims, except as provided in Section 8. 

This Release Is Extremely Broad. This release is meant to be as broad as legally permissible and applies to both
employment-related and non-employment-related Claims up to the time that you execute this Agreement. This release includes a waiver of jury trials and non-jury trials.
This Agreement does not release or waive Claims or rights that, as a matter of law, cannot be waived, which include, but are not necessarily limited to, the exceptions to your release of claims or covenant not to sue referenced in Section 8.

  

	7.	 YOU ARE AGREEING NOT TO SUE 

Except as provided in Section 8, you agree not to sue or otherwise bring any legal action against the Company or any of
the Releasees ever for any Claim released in Section 6 arising before you Execute this Agreement. You are not only waiving any right you may have to proceed individually, but also as a member of a class or collective action. You waive any and
all rights you may have had to receive notice of any class or collective action against Releasees for claims arising before you Execute this Agreement. In the event that you receive notice of a class or collective action against Releasees for claims
arising before you Execute this Agreement, you must “opt out” of and may not “opt in” to such action. You are also giving up any right you may have to recover any relief, including money damages, from the Releasees as a member of
a class or collective action. 

  
 5 

	8.	 Exceptions To Your Release Of Claims And Covenant Not To Sue 

In Sections 6 and 7, you are releasing Claims and agreeing not to sue, but there are exceptions to those commitments.
Specifically, nothing in this Agreement prevents you from bringing a legal action or otherwise taking steps to: 
  

	 	•	 	 Enforce the terms of this Agreement; or 

 

	 	•	 	 Challenge the validity of this Agreement; or 

 

	 	•	 	 Make any disclosure of information required by law; or 

 

	 	•	 	 Provide information to, testify before or otherwise assist in any investigation or proceeding brought by, any
regulatory or law enforcement agency or legislative body, any self-regulatory organization, or the Company; or 

  

	 	•	 	 Provide truthful testimony in any forum; or 

 

	 	•	 	 Cooperate fully and provide information as requested in any investigation by a governmental agency or
commission; or 

  

	 	•	 	 File a charge or complaint with the Equal Employment Opportunity Commission, the National Labor Relations
Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (“Government Agencies”); or 

 

	 	•	 	 File a lawsuit or other action to pursue Claims that arise after you Execute this Agreement.

 For purposes of clarity, this Agreement does not limit your ability to communicate with any Government
Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. This Agreement does not limit your right to
receive an award for information provided to any Government Agencies. 
  

	9.	 Your Continuing Obligations. 

You acknowledge and re-affirm your continuing obligations pursuant to the Employment
Agreement and the NDA executed between you and the Company, including your confidentiality obligations under Section 2 of the NDA and any restrictions under Sections 4 and 5 of the NDA 

Pursuant to the Defend Trade Secrets Act of 2016, you acknowledge and understand that you will not be held criminally or
civilly liable under any federal or state trade secret law for the disclosure of the trade secrets of the Company or any of its affiliates that is made by you (i) in confidence to a federal, state, or local government official, either directly
or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law, or (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. 

 

	10.	 Return Of Property. 

As of your Termination Date, you agree that you have returned to the Company all property belonging to the Company including,
but not limited to, electronic devices, equipment, access cards, and paper and electronic documents obtained in the course of your employment. 

  
 6 

	11.	 Prior Disclosures. 

You acknowledge that, prior to the termination of your employment with the Company, you disclosed to the Company, in accordance
with applicable policies and procedures, any and all information relevant to any investigation of the Company’s business practices conducted by any governmental agency or to any existing, threatened or anticipated litigation involving the
Company, whether administrative, civil or criminal in nature, and that you are otherwise unaware of any wrongdoing committed by any current or former employee of the Company that has not been disclosed. Nothing in this Agreement shall prohibit or
restrict you or the Company from (1) making any disclosure of information required by law; (2) providing information to, or testifying or otherwise assisting in any investigation or proceeding brought by any federal or state regulatory or
law enforcement agency or legislative body, any self-regulatory organization, or with respect to any internal investigation by the Company or its affiliates; or (3) testifying, participating in or otherwise assisting in a proceeding relating to
an alleged violation of the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, any federal, state or municipal law relating to fraud, or any rule or regulation of any self-regulatory organization. 

 

	12.	 Non-Disparagement 

You agree that you will not, through any medium including, but not limited to, the press, Internet or any other form of
communication, disparage, defame, or otherwise damage or assail the reputation, integrity or professionalism of the Company or the Releasees. Nothing in this Section 12 is intended to restrict or impede your participation in proceedings or
investigations brought by or before the EEOC, NLRB, or other federal, state or local government agencies, or otherwise exercising protected rights to the extent that such rights cannot be waived by agreement, including Section 7 rights under
the National Labor Relations Act. 
  

	13.	 The Company’s Remedies For Breach. 

If you breach any section of this Agreement, including without limitation, Section 6, 7, or 12 or otherwise seek to bring
a Claim given up under this Agreement, the Company will be entitled to all relief legally available to it including equitable relief such as injunctions, and the Company will not be required to post a bond.  

 

	14.	 Governing Law. 

This Agreement is governed by New York law, without regard to conflicts of laws principles.  

 

	15.	 Successors And Assigns. 

This Agreement is binding on the Parties and their heirs, executors, successors and assigns. 

 

	16.	 Severability And Construction. 

If a court with jurisdiction to consider this Agreement determines that any provision is illegal, void or unenforceable, that
provision will be invalid. However, the rest of the Agreement will remain in full force and effect. A court with jurisdiction to consider this Agreement may modify invalid provisions if necessary to achieve the intent of the Parties. 

  
 7 

	17.	 No Admission. 

By entering into this Agreement, neither you nor the Company admits wrongdoing of any kind. 

 

	18.	 Do Not Rely On Verbal Statements. 

 

	 	•	 	 This Agreement sets forth the complete understanding between the Parties. 

 

	 	•	 	 This Agreement may not be changed orally. 

 

	 	•	 	 This Agreement constitutes and contains the complete understanding of the Parties with regard to the end of
your employment and supersedes and replaces all prior oral and written agreements and promises between the Parties, except that, as set forth in Section 5, your restrictive covenant obligations remain in full force and effect.

  

	 	•	 	 Neither the Company nor any representative (nor any representative of any other company affiliated with the
Company), has made any promises to you other than as written in this Agreement. All future promises and agreements must be in writing and signed by both Parties. 

 

	19.	 Your Opportunity To Review and Revoke. 

 

	 	•	 	 Twenty-One Day Review Period. You have twenty-one (21) calendar days from the day you receive this Agreement to consider the terms of this Agreement, sign it and return it to Head of HR, Dermavant Sciences, Inc., 2398 E. Camelback Rd. Suite 280,
Phoenix, AZ 85016, with a copy to General Counsel, Roivant Sciences, Inc., 320 w 37th Street, 6th Floor, New York, NY 10018. Your opportunity
to accept the terms of this Agreement will expire at the conclusion of the twenty-one (21) calendar day period if you do not accept those terms before time expires. That means that your opportunity to accept
the terms of this Agreement will expire on September 25, 2018. You may sign the Agreement in fewer than twenty-one (21) calendar days, if you wish to do so. If you elect to do so, you acknowledge that you have
done so voluntarily. Your signature below indicates that you are entering into this Agreement freely, knowingly and voluntarily, with full understanding of its terms. 

 

	 	•	 	 Talk To A Lawyer. During the twenty-one (21) calendar-day review period, and before executing this Agreement, the Company advises you to consult with an attorney, at your own expense, regarding the terms of this Agreement. 

 

	 	•	 	 Seven Days to Change Your Mind. You have seven (7) calendar days from the date of
signing this Agreement to revoke the Agreement by expressing a desire to do so in writing addressed to Head of HR, Dermavant Sciences, Inc., 2398 E. Camelback Rd. Suite 280, Phoenix, AZ 85016, email address: jen.lustig@dermavant.com, with a copy to
General Counsel, Roivant Sciences, Inc., 320 w 37th Street, 6th Floor, New York, NY 10018, email address: allen.waxman@roivant.com.

  
 8 

	20.	 We Want To Make Absolutely Certain That You Understand This Agreement. 

You acknowledge and agree that: 
  

	 	•	 	 You have carefully read this Agreement in its entirety; 

 

	 	•	 	 You have had an opportunity to consider the terms of this Agreement for at least twenty-one (21) calendar days; 

  

	 	•	 	 You understand that the Company urges you to consult with an attorney of your choosing, at your expense,
regarding this Agreement; 

  

	 	•	 	 You have the opportunity to discuss this Agreement with a lawyer of your choosing, and agree that you had a
reasonable opportunity to do so, and he or she has answered to your satisfaction any questions you asked with regard to the meaning and significance of any of the provisions of this Agreement; 

 

	 	•	 	 You fully understand the significance of all of the terms and conditions of this Agreement; and

  

	 	•	 	 You are executing this Agreement voluntarily and of your own free will and agree to all the terms and
conditions contained in this Agreement. 

  
 9 

 YOU AGREE THAT ANY MODIFICATIONS, MATERIAL OR OTHERWISE, MADE TO THIS AGREEMENT DO NOT
RESTART, EXTEND OR AFFECT IN ANY MANNER THE ORIGINAL REVIEW PERIOD DESCRIBED ABOVE. 
  

							
	 /s/ Chris Van Tuyl
	 		 	 /s/ Jacqualyn Fouse, Ph.D.

	  

DERMAVANT SCIENCES, INC.
	 		 	  

        Jacqualyn Fouse, Ph.D.

				
	 By:
	 	 Chris Van Tuyl
	 		 	
				
	 Dated:
	 	 Sept. 5, 2018
	 		 	     Dated: Sept. 5, 2018

  
 10EX-10.35

 

 
  

 Exhibit 10.35 

DERMAVANT SCIENCES, INC. 

EMPLOYMENT AGREEMENT 

This Employment Agreement (this “Agreement”) is entered into as of October 27, 2018, by and between Todd
Zavodnick (the “Executive”) and Dermavant Sciences, Inc. (the “Company”). 

RECITALS 

A. The Company desires the association and services of the Executive and the Executive’s skills, abilities, background and
knowledge, and is willing to engage the Executive’s services on the terms and conditions set forth in this Agreement. 
 B. The
Executive desires to be in the employ of the Company, and is willing to accept such employment on the terms and conditions set forth in this Agreement. 

C. This Agreement supersedes any and all prior and contemporaneous oral or written employment agreements or arrangements between the
Executive and the Company or any predecessor thereof. 
 AGREEMENT 

In consideration of the foregoing, the parties agree as follows: 
  

	 	1.	 EMPLOYMENT BY THE COMPANY.

 1.1 Position; Duties. Subject to the terms and conditions of this Agreement, the
Executive shall hold the position of Chief Executive Officer of the Company. In this position, the Executive will have the duties and authorities normally associated with a chief executive officer of a company. The Executive will report to, and be
subject to the direction of, the Board of Directors of Dermavant Sciences Ltd. (the “Board”). The Executive shall devote the Executive’s full business energies, interest, abilities and productive time to the proper and
efficient performance of the Executive’s duties under this Agreement; provided, however, that the Executive may devote reasonable periods of time to (a) serving on the board of directors of other corporations subject to the
prior approval of the Board, and (b) engaging in charitable or community service activities, so long as none of the foregoing additional activities materially interfere with the Executive’s duties under this Agreement. 

1.2 Service to Affiliates. It is understood and agreed that the Executive’s duties may include providing
services to or for the benefit of the Company’s affiliates, including, but not limited to, Dermavant Sciences Ltd. (the “Parent”), provided, that the Executive agrees that the Executive will not provide any
services from within the United States for the Parent or any affiliate 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 
of the Parent that is organized in a jurisdiction outside the United States. The Executive will not become an employee of the Parent, and the Executive’s activities in respect of services to
the Parent shall be strictly ministerial and shall not involve conducting any of the Parent’s business activities from within the United States, including
day-to-day management or other operational activities of the Parent. 

1.3 Location of Employment. The Executive’s principal place of employment shall be the Company’s
offices to be established in or near Irvine, California. The Executive understands that the Executive’s duties may require extensive business travel. 

1.4 Policies and Procedures. The employment relationship between the parties shall be governed by this Agreement
and by the policies and practices established by the Company and/or its Board. In the event that the terms of this Agreement differ from or are in conflict with the Company’s policies or practices, this Agreement shall govern and control. 

1.5 Exclusive Employment; Agreement not to Compete. Subject to Section 1.1 and 1.2 above, except with the
prior written consent of the Board, the Executive will not, during the Executive’s employment with the Company, undertake or engage in any other employment, occupation or business enterprise. During the Executive’s employment, the
Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by the Executive to be adverse or antagonistic to the Company, its business, or prospects, financial or otherwise, or in
any company, person, or entity that is, directly or indirectly, in competition with the business of the Company. Ownership by the Executive in professionally managed funds over which the Executive does not have control or discretion in investment
decisions, or, an investment of less than two percent (2%) of the outstanding shares of capital stock of any corporation with one or more classes of its capital stock listed on a national securities exchange or publicly traded on a national
securities exchange or in the over-the-counter market shall not constitute a breach of this Section. 

1.6 Start Date. The Executive’s employment with the Company shall commence on or before November 15,
2018 (the “Start Date”). 
  

	 	2.	 AT-WILL EMPLOYMENT. 

The Executive’s employment relationship with the Company is, and shall at all times remain,
at-will. This means that either the Executive or the Company may terminate the employment relationship at any time, for any reason or for no reason, with or without Cause (as defined below) or advance notice;
provided, however, the Executive must provide the Company at least three (3) months’ advance written notice of the Executive’s intention to resign from employment (except for a resignation for Good Reason, in which case
such procedure shall be governed by the terms set forth in the definition of Good Reason) and the Company shall provide the Executive written notice in the event of a termination of the Executive’s employment by the Company without Cause. 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

	 	3.	 COMPENSATION AND BENEFITS. 

3.1 Salary and Signing Bonus. 

(a) The Company shall pay the Executive a base salary at the annualized rate of four hundred fifty thousand dollars
($450,000) (the “Base Salary”), less payroll deductions and all required withholdings, payable in regular periodic payments in accordance with the Company’s normal payroll practices. The Base Salary shall be prorated for
any partial year of employment on the basis of a 365-day year. The Base Salary shall be subject to periodic review and may be adjusted from time to time in the Board’s discretion. 

(b) The Company shall pay the Executive a one-time signing bonus of four
hundred fifty-six thousand dollars ($456,000) within sixty (60) days of the Executive’s Start Date (the “Signing Bonus”), less payroll deductions and all required
withholdings. If the Executive resigns from employment with the Company without Good Reason or the Company terminates the Executive’s employment for Cause, in each case prior to the first anniversary of the Start Date, the Executive must repay
the Signing Bonus in full to the Company. If any repayment is due to the Company pursuant to this Section, the Executive agrees that the amount of the repayment due is payable in full immediately via personal check or payroll deduction and the
Executive agrees to permit the Company to deduct this amount from any monies or benefits due to the Executive including wages, bonuses, reimbursements and/or expenses and any remaining amounts are the Executive’s responsibility, payable via
personal check. 
 3.2 Annual Performance Bonus. Beginning with the fiscal year commencing on April 1,
2019, each fiscal year the Executive will be eligible to earn an annual discretionary cash bonus (the “Annual Performance Bonus”) with a target bonus opportunity equal to sixty percent (60%) of the Executive’s Base
Salary, based on the Board’s assessment of the Executive’s individual performance and overall Company performance. In order to earn and receive the Annual Performance Bonus, the Executive must remain employed by the Company through and
including the date on which the Annual Performance Bonus is paid. The Annual Performance Bonus, if any, will be paid no later than thirty (30) days following the end of the Company’s fiscal year (March 31st), or by April 30th. The Annual
Performance Bonus payable, if any, shall be prorated for the initial year of employment (on the basis of a three hundred sixty-five (365)-day year) and shall be prorated if the Company’s review or
assessment of the Executive’s performance covers a period that is less than a full fiscal year. The determination of whether the Executive has earned a bonus and the amount thereof shall be determined by the Board (and/or a committee thereof)
in its sole discretion. The Board (and/or a committee thereof) reserves the right to modify the bonus criteria from year to year. 
 3.3
Equity. 
 (a) Subject to the terms of the Parent’s 2016 Equity Incentive Plan (the “Plan”) and approval of
the grant by the Board, the Executive will be granted an award of an option to purchase shares of Parent common stock equating to three and six-tenths percent (3.6%) of the total outstanding fully-diluted
shares of the Parent at the time of the grant (the “Option 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 
Award”). The Option Award will be granted on or around the twentieth (20th) day of the month following the Executive’s Start Date, with an exercise price
equal to the fair market value of Parent’s common stock on such date of grant, as set forth in the Plan, and will be subject to a four (4) year vesting period, with (i) twenty-five percent (25%) of the Option Award vesting on the one-year anniversary of the Start Date and (ii) the balance of the Option Award vesting in a series of twelve (12) successive equal quarterly installments measured from the first (1st) anniversary of the
Start Date, provided the Executive is employed by the Company on each such vesting date. The Option Award will be governed by the Plan and other documents issued in connection with the grant. 

(b) The Executive may be eligible to receive additional discretionary annual equity incentive grants in amounts and on terms and
conditions determined by the Board in its sole discretion. 
 3.4 Benefits and Insurance. The Executive shall, in
accordance with Company policy and the terms of the applicable plan documents, be eligible to participate in benefits under any benefit plan or arrangement that may be in effect from time to time and made available to similarly situated
Company executives (including, but not limited to, being named as an officer for purposes of the Company’s Directors & Officers insurance policy). The Company reserves the right in its sole discretion to modify, add or eliminate
benefits at any time. All benefits shall be subject to the terms and conditions of the applicable plan documents, which may be amended or terminated at any time. The Executive shall be entitled to vacation each year, in addition to sick leave and
observed holidays in accordance with the policies and practices of the Company. Vacation may be taken at such times and intervals as the Executive shall determine, subject to the business needs of the Company. 

3.5 Expense Reimbursements. The Company will reimburse the Executive for all reasonable business expenses that
the Executive incurs in conducting the Executive’s duties hereunder, pursuant to the Company’s usual expense reimbursement policies. Reimbursement will be made as soon as practicable following receipt from the Executive of reasonable
documentation supporting said expenses. 
  

	 	4.	 PROPRIETARY INFORMATION OBLIGATIONS.

 As a condition of employment, the Executive agrees to execute and abide by the Company’s Employee Non-Disclosure, Invention Assignment and Restrictive Covenant Agreement (“NDA”). 
  

	 	5.	 TERMINATION OF EMPLOYMENT. 

5.1 Termination Without Cause Or Resignation For Good Reason. If the Company terminates the Executive’s
employment without Cause or the Executive resigns for Good Reason (as defined below), the Company shall pay the Executive any earned but unpaid Base Salary and unused vacation accrued (if applicable) through the date of termination, at the rates
then in effect, less standard deductions and withholdings. In addition, if the Executive 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 
furnishes to the Company an executed waiver and release of claims in the form substantially similar to that attached hereto as Exhibit A, with any changes that the Company determines are
necessary to comply with applicable law (the “Release”), which Release is non-revocable prior to the Release Date (as defined below), and if the Executive allows the Release to become
effective in accordance with its terms, then the Executive shall receive: (A) reimbursement by the Company of insurance coverage under COBRA, subject to Executive’s election and period of eligibility for such coverage, until the earlier of
nine (9) months from the date of the termination of employment, or until Executive becomes eligible to be covered under a subsequent employer’s group health insurance plan, and (B) an aggregate amount equal to nine (9) months of
the Executive’s then-current Base Salary, payable in equal installments over the nine (9) month period following the date of the Executive’s termination in accordance with customary payroll practices, but no less frequently than
monthly. Such payments shall commence within ten (10) days following the Release Date and will be subject to required withholding. 

5.2 Termination or Resignation Following a Change of Control. If the Company terminates the Executive’s
employment without Cause or the Executive resigns for Good Reason within twelve (12) months following the closing date of a Change of Control, the Company shall pay the Executive any earned but unpaid Base Salary and unused vacation accrued (if
applicable) through the date of termination, at the rates then in effect, less standard deductions and withholdings. In addition, if the Executive furnishes to the Company an executed waiver and release of claims in the form substantially similar to
that attached hereto as Exhibit A, with any changes that the Company determines are necessary to comply with applicable law (the “Release”), which Release is non-revocable prior to the
Release Date (as defined below), and if the Executive allows the Release to become effective in accordance with its terms, then: (A) reimbursement by the Company of insurance coverage under COBRA, subject to Executive’s
election and period of eligibility for such coverage, until the earlier of twelve (12) months from the date of the termination of employment, or until Executive becomes eligible to be covered under a subsequent employer’s group health
insurance, (B) the Executive shall receive an aggregate amount equal to twelve (12) months of the Executive’s then-current Base Salary plus one hundred percent (100%) of the Executive’s then-current target Annual Performance
Bonus, payable in equal installments over the twelve (12) month period following the date of the Executive’s termination in accordance with customary payroll practices, but no less frequently than monthly, and (C) any unvested portion
of the Executive’s Option Award shall immediately vest in full. Any payments required by this Section 5.2 shall commence within ten (10) days following the Release Date and will be subject to required withholding. 

5.3 Other Termination. If the Executive resigns from employment with the Company at any time without Good Reason
or the Company terminates the Executive’s employment at any time for Cause or due to death or Disability (as defined below), the Company shall pay the Executive (or the Executive’s estate) any earned but unpaid Base Salary and any unused
vacation accrued (if applicable) through the date of such resignation or termination, at the rates then in effect, less standard deductions and withholdings. The Company shall thereafter have no further obligations to the Executive, except as may
otherwise be required by law. 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 5.4 Definitions. For purposes of this Agreement, the following terms
shall have the following meanings: 
 (a) “Cause” shall mean the occurrence of any of
the following, the Executive’s: (i) conviction of, or plea of no contest to, any felony or any crime involving moral turpitude or dishonesty; (ii) participation in a fraud against the Company; (iii) willful and
material breach of the Executive’s duties and obligations under this Agreement or any other agreement between the Executive and the Company or its affiliates that has not been cured (if curable) within thirty (30) days after receiving
written notice from the Board of such breach; (iv) engagement in conduct that causes or is reasonably likely to cause material damage to the Company’s property or reputation; (v) material failure to comply with the Company’s Code
of Conduct or other material policies; or (vi) violation of any law, rule or regulation (collectively, “Law”) relating in any way to the business or activities of the Company or its subsidiaries or affiliates, or other
Law that is violated during the course of the Executive’s performance of services hereunder that results in the Executive’s arrest, censure, or regulatory suspension or disqualification, including, without limitation, the Generic Drug
Enforcement Act of 1992, 21 U.S.C. § 335(a), or any similar legislation applicable in the United States or in any other country where the Company intends to develop its activities. 

(b) “Change of Control” shall have the same meaning as such term is defined in the Dermavant
Sciences Ltd. 2016 Equity Incentive Plan. 
 (c) “Disability” shall mean the Executive’s
inability to perform the Executive’s duties and responsibilities hereunder, with or without reasonable accommodation, due to any physical or mental illness or incapacity, which condition has continued for a period of one hundred
eighty (180) days (including weekends and holidays) in any consecutive three hundred sixty-five (365) day period. 

(d) “Good Reason” shall mean the occurrence of any of the following events
without the Executive’s consent: (i) a material reduction of the Executive’s Base Salary as initially set forth herein or as the same may be increased from time to time, provided, however, that if such reduction occurs
in connection with a Company-wide decrease in executive officer team compensation, such reduction shall not constitute Good Reason provided that it is a reduction of a proportionally like amount or percentage affecting the entire executive team not
to exceed ten percent (10%); or (ii) material reduction in the Executive’s authority, duties or responsibilities, as compared to the Executive’s authority, duties or responsibilities immediately prior to such reduction;
provided, however, any resignation by the Executive shall only be deemed for Good Reason pursuant to this definition if: (1) the Executive gives the Company written notice of the Executive’s intent to terminate for Good
Reason within thirty (30) days following the first occurrence of the condition(s) that the Executive believes constitute(s) Good Reason, which notice shall describe such condition(s); (2) the Company fails to remedy such condition(s) within
thirty (30) days following receipt of the written notice (the “Cure Period”); and (3) the Executive voluntarily resigns from employment with the Company within thirty (30) days following the end of the Cure Period.

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 (e) “Release Date” shall mean the date that
is fifty-five (55) days following the date of the Executive’s termination. 
 5.5 Effect of Termination. The
Executive agrees that should the Executive’s employment terminate for any reason, the Executive shall be deemed to have resigned from any and all positions with the Company, including, but not limited to, the Executive’s position on
any board (whether for Dermavant or any affiliate of Dermavant). 
 5.6 Section 409A Compliance. 

(a) It is intended that any benefits under this Agreement satisfy, to the greatest extent possible, the exemptions from
the application of Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”), provided under Treasury Regulations Sections
1.409A-1(b)(4), and 1.409A-1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so
exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A. For purposes of Section 409A (including, without limitation, for purposes of Treasury Regulations Section 1.409A-2(b)(2)(iii)), the Executive’s right to receive any installment payments under this Agreement (whether severance payments, if any, or otherwise) shall be treated as a right to receive a
series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. A termination of employment shall not be deemed to have occurred for purposes of any provision of this
Agreement providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of Section 409A and, for purposes of any such
provision of this Agreement, references to a “resignation,” “termination,” “termination of employment” or like terms shall mean separation from service. In no event may Executive, directly or indirectly, designate the
calendar year of a payment. Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of the Executive’s execution of the Release, directly or indirectly, result in the Executive designating the calendar year
of payment of any amounts of deferred compensation subject to Section 409A, and if a payment that is subject to execution of the Release could be made in more than one taxable year, payment shall be made in the later taxable year. The Company
makes no representation or warranty and shall have no liability to the Executive or any other person if any compensation under this Agreement constitutes deferred compensation subject to Code Section 409A but does not satisfy an exemption from,
or the conditions of, Code Section 409A. 
 (b) Notwithstanding any provision to the contrary in this Agreement,
if the Executive is deemed by the Company at the time of a separation from service to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i), and if any payments or benefits that the Executive becomes entitled to under
this Agreement on account of such separation from service are deemed to be “deferred compensation,” then to the extent delayed commencement of any portion of such payments or benefits is required in order to avoid a prohibited distribution
under Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided prior to the earliest of (i) the expiration of the six (6)-month period measured from 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 
the date of separation from service, (ii) the date of the Executive’s death or (iii) such earlier date as permitted under Section 409A without the imposition of adverse
taxation. Upon the first (1st) business day following the expiration of such period, all payments deferred pursuant to this paragraph shall be paid in a lump sum, and any remaining payments due shall be paid as otherwise provided herein. No interest
shall be due on any amounts so deferred. 
 (c) With regard to any provision herein that provides for reimbursement
of costs and expenses or in-kind benefits, except as permitted by Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to
liquidation or exchange for another benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for
reimbursement, or in-kind benefits to be provided, in any other taxable year, and (iii) such payments shall be made on or before the last day of the Executive’s taxable year following the taxable
year in which the expense was incurred. 
 5.7 Section 280G. 

(a) If any payment or benefit (including payments and benefits pursuant to this Agreement) that the Executive would
receive in connection with a change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company determined in accordance with Section 280G(b)(2) of the Code (a
“Transaction”) from the Company or otherwise (“Transaction Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Internal Revenue Code of
1986, as amended (the “Code”), and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the Company shall cause to be
determined, before any amounts of the Transaction Payment are paid to the Executive, which of the following two alternative forms of payment would result in the Executive’s receipt, on an after-tax basis,
of the greater amount of the Transaction Payment notwithstanding that all or some portion of the Transaction Payment may be subject to the Excise Tax: (1) payment in full of the entire amount of the Transaction Payment (a “Full
Payment”), or (2) payment of only a part of the Transaction Payment so that the Executive receives the largest payment possible without the imposition of the Excise Tax (a “Reduced Payment”). For purposes of
determining whether to make a Full Payment or a Reduced Payment, the Company shall cause to be taken into account the value of all applicable federal, state and local income and employment taxes and the Excise Tax (all computed at the highest
applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes). If a Reduced Payment is made, (x) the Executive shall have no rights to any additional payments
and/or benefits constituting the Transaction Payment, and (y) reduction in payments and/or benefits shall occur in the manner that results in the greatest economic benefit to the Executive as determined in this paragraph. If more than one
method of reduction will result in the same economic benefit, the portions of the Transaction Payment shall be reduced pro rata. 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 (b) Notwithstanding the foregoing, in the event that no stock of the
Company is readily tradeable on an established securities market or otherwise (within the meaning of Section 280G of the Code) at the time of the Transaction, the Company shall cause a vote of shareholders to be held to approve the portion of
the Transaction Payments that equals or exceeds three times (3x) the Executive’s “base amount” (within the meaning of Section 280G of the Code) (the “Excess Parachute Payments”) in accordance with Treas.
Reg. §1.280G-1, and the Executive shall cooperate with such vote of shareholders, including the execution of any required documentation subjecting the Executive’s entitlement to all Excess Parachute
Payments to such shareholder vote. In the event that the Company does not cause a vote of shareholder to be held to approve all Excess Parachute Payments, or the shareholders do not approve all Excess Parachute Payments, the provisions set forth in
Section 5.6(a) of this Agreement shall apply. 
 (c) Unless the Executive and the Company otherwise agree in
writing, any determination required under this section shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose determination shall be conclusive and binding upon the Executive
and the Company for all purposes. For purposes of making the calculations required by this section, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations
concerning the application of Sections 280G and 4999 of the Code. The Accountants shall provide detailed supporting calculations to the Company and the Executive as requested by the Company or the Executive. The Executive and the Company shall
furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this section. The Company shall bear all costs the Accountants may reasonably incur in connection with any
calculations contemplated by this section. 
  

	 	6.	 ARBITRATION. 

Except as otherwise set forth below in connection with equitable remedies, any dispute, claim or controversy arising out of or
relating to this Agreement or the Executive’s employment with the Company (collectively, “Disputes”), including, without limitation, any dispute, claim or controversy concerning the validity, enforceability, breach or
termination of this Agreement, if not resolved by the parties, shall be finally settled by arbitration in accordance with the then-prevailing Employment Arbitration Rules and Procedures of JAMS, as modified herein (“Rules”).
The requirement to arbitrate covers all Disputes (other than disputes which by statute are not arbitrable) including, but not limited to, claims, demands or actions under the Age Discrimination in Employment Act (including Older Workers Benefit
Protection Act); Americans with Disabilities Act; Civil Rights Act of 1866; Civil Rights Act of 1991; Employee Retirement Income Security Act of 1974; Equal Pay Act; Family and Medical Leave Act of 1993; Title VII of the Civil Rights Act of 1964;
Fair Labor Standards Act; Fair Employment and Housing Act; and any other law, ordinance or regulation regarding discrimination or harassment or any terms or conditions of employment. There shall be one arbitrator who shall be jointly selected by the
parties. If the parties have not jointly agreed upon an arbitrator within twenty (20) calendar days of respondent’s receipt of claimant’s notice of intention to arbitrate, either party may request JAMS to furnish the parties with a
list of names from which the parties shall jointly select an arbitrator. If the parties have not agreed upon an arbitrator within ten (10) calendar days of the transmittal date of such list, then each party shall have an additional five
(5) calendar days in 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 
which to strike any names objected to, number the remaining names in order of preference, and return the list to JAMS, which shall then select an arbitrator in accordance with the Rules. The
place of arbitration shall be New York, New York. By agreeing to arbitration, the parties hereto do not intend to deprive any court of its jurisdiction to issue a pre-arbitral injunction, including, without
limitation, with respect to the NDA. The arbitration shall be governed by the Federal Arbitration Act, 9 U.S.C. §§ 1-16. Judgment upon the award of the arbitrator may be entered in any court of
competent jurisdiction. The arbitrator shall: (a) have authority to compel discovery which shall be narrowly tailored to efficiently resolve the disputed issues in the proceeding; and (b) issue a written statement signed by the arbitrator
regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The Company shall pay all administrative
fees of JAMS in excess of four hundred thirty-five dollars ($435) (a typical filing fee in court) but the Company and the Executive shall split any arbitrator’s fees and expenses. Each party shall bear its or his/her own costs and expenses
(including attorney’s fees) in any such arbitration and the arbitrator shall have no power to award costs and attorney’s fees except as provided by statute or by separate written agreement between the parties. In the event any portion of
this arbitration provision is found unenforceable by a court of competent jurisdiction, such portion shall become null and void leaving the remainder of this arbitration provision in full force and effect. The parties agree that all information
regarding the arbitration, including any settlement thereof, shall not be disclosed by the parties hereto, except as otherwise required by applicable law. 
  

	 	7.	 GENERAL PROVISIONS. 

7.1 Representations and Warranties. 

(a) The Executive represents and warrants that the Executive is not restricted or prohibited, contractually or
otherwise, from entering into and performing each of the terms and covenants contained in this Agreement, and that the Executive’s execution and performance of this Agreement will not violate or breach any other agreements between the Executive
and any other person or entity. The Executive represents and warrants that the Executive is not subject to any confidentiality or non-competition agreement or any other similar type of restriction that could
restrict in any way the Executive’s hiring by the Company and the performance of the Executive’s expected job duties with the Company. 

(b) The Company and its affiliates do not wish to incorporate any unlicensed or unauthorized material, or otherwise use
such material in any way in connection with, its and their respective products and services. Therefore, the Executive hereby represents, warrants and covenants that the Executive has not and will not disclose to the Company or its affiliates, use in
their business, or cause them to use, any information or material which is a trade secret, or confidential or proprietary information, of a third party, including, but not limited to, any former employer, competitor or client, unless the Company or
its affiliates have a right to receive and use such information or material. 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 (c) The Executive represents and warrants that the Executive is not
debarred and has not received notice of any action or threat with respect to debarment under the provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C. § 335(a) or any similar legislation applicable in the United States or in any
other country where the Company intends to develop its activities. The Executive understands and agrees that this Agreement is contingent on the Executive’s submission of satisfactory proof of identity and legal authorization to work in the
United States, as well as verification of auditor independence. 
 7.2 Advertising Waiver. The Executive agrees to
permit the Company, and persons or other organizations authorized by the Company, to use, publish and distribute advertising or sales promotional literature concerning the products and/or services of the Company in which the Executive’s
name and/or pictures of the Executive appear. The Executive hereby waives and releases any claim or right the Executive may otherwise have arising out of such use, publication or distribution. 

7.3 Miscellaneous. 

(a) This Agreement, along with the NDA and any applicable equity awards that have been granted, constitutes the
complete, final and exclusive embodiment of the entire agreement between the Executive and the Company with regard to its subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those
expressly contained herein, and it supersedes any other such promises, warranties or representations. 
 (b) This
Agreement may not be modified or amended except in a writing signed by both the Executive and a duly authorized officer or member of the Board. 

(c) This Agreement will bind the heirs, personal representatives, successors and assigns of both the Executive and the
Company, and inure to the benefit of both the Executive and the Company, and to the Executive’s and the Company’s heirs, successors and assigns, as applicable, except that the duties and responsibilities of the Executive are of a personal
nature and shall not be assignable or delegable in whole or in part by the Executive. The Company may assign its rights, together with its obligations hereunder, in connection with any merger, consolidation, or transfer or other disposition of all
or substantially all of its assets, and such rights and obligations shall inure to, and be binding upon, any successor to the Company or any successor to all or substantially all of the assets of the Company, which successor shall expressly assume
such obligations. 
 (d) If any provision of this Agreement is determined to be invalid or unenforceable, in whole or
in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified so as to be rendered enforceable. 

(e) This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the
laws of the State of New York as applied to contracts made and to be performed entirely within New York. 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 (f) Any ambiguity in this Agreement shall not be construed against
either party as the drafter. Any waiver of a breach of this Agreement shall be in writing and shall not be deemed to be a waiver of any successive breach. This Agreement may be executed in counterparts and facsimile signatures will suffice as
original signatures. 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 IN WITNESS WHEREOF, the parties have
executed this Agreement as of the day and year first written above. 
  

			
	DERMAVANT SCIENCES, INC.
		
	By:	 	 /s/ Frank Torti

	Name:	 	Frank Torti
	Title:	 	Chairman, Dermavant Sciences Ltd.

  

	
	ACCEPTED AND AGREED:
	
	 /s/ Todd Zavodnick

	Todd Zavodnick

 10/27/18 

  
  

					
		  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 EXHIBIT A: 

RELEASE FORM 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 [DATE] 

[NAME] 
 [ADDRESS] 

[CITY], New York [ZIP] 
 RE: Separation
Agreement and General Release 
 Dear [FIRST NAME], 

Your employment with Dermavant Sciences, Inc. will be terminated effective [DATE OF TERMINATION]. This Separation Agreement and
General Release (this “Agreement”) sets forth the terms and conditions under which [•] Sciences, Inc. is offering you additional pay and benefits in exchange for you making and honoring certain commitments, including agreeing not to
pursue legal action against the Company as described in Sections 7 and 8. 
 PLEASE NOTE: THIS DOCUMENT HAS IMPORTANT
LEGAL CONSEQUENCES TO YOU. YOU SHOULD CONSULT AN ATTORNEY OF YOUR CHOICE, AT YOUR EXPENSE, PRIOR TO EXECUTING IT. 
  

	1.	 Parties To This Agreement 

This letter is a proposed agreement that Dermavant Sciences, Inc. is offering to you. In this document, references to
[NAME] refer to “you” and DERMAVANT SCIENCES, INC. is referred to as “Dermavant” or the “Company.” Together, you and Dermavant are referred to as the “Parties.” 

 

	2.	 What You Will Receive Regardless of Whether You Enter Into This Agreement Whether or not you enter
into this Agreement, you will receive the following: 

  

	 	a.	 Your regular base pay (less applicable withholding) through [SEPARATION DATE], provided you remain employed
at the Company through that date. You will be receiving your regular pay in the same manner that you normally receive your regular pay, such as direct deposit, consistent with established bi-monthly pay cycles
as long as you remain employed; and 

  

	 	b.	 If you are currently enrolled and participating in the Company’s medical/dental/vision benefits, your
coverage will extend until the end of [SEPARATION MONTH] (the month in which your separation takes place) OR [SIX (6) MONTHS FOLLOWING YOUR DATE OF TERMINATION]. Thereafter, you will be able to continue as a member of the Company’s Group
Health Plans at your expense in accordance with the terms of those plans, as well as COBRA, for the legally required benefit continuation period. You will be receiving a separate letter explaining your rights and responsibilities with regard to
electing your COBRA benefits; and 

  

	 	c.	 Accrued vested benefits under any applicable retirement plans offered by the Company. You will receive
information directly from Fidelity and you may direct questions to them at 1-800-603-4015; and 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

	 	d.	 Reimbursement for all approved business-related expenses incurred up to your last day of employment
consistent with established travel and expense policies; and 

  

	 	e.	 As long as you direct reference inquiries from potential employers to the Head of Human Resources of the
Company or their designee, [Address], unless otherwise authorized in writing, the Company will limit information it discloses in response to reference requests to: (1) your dates of employment; and (2) your last
position held. Of course, the Company reserves the right to respond truthfully to any compulsory process of law (such as a subpoena) or as otherwise required by law. 

 

	3.	 What You Will Receive Only If You Enter Into This Agreement. 

As long as you timely sign, date and return this Agreement (BUT IN NO CASE LATER THAN [LAST DATE TO ACCEPT (21
CALENDAR DAYS FOLLOWING RECEIPT)], and you comply with the Agreement’s requirements, then in addition to those payments and benefits described in Paragraph 2 above: 

 

	 	•	 	 You will receive salary continuation benefit payments at your regular Base Salary through [SEVERANCE END DATE]
subject to applicable withholdings; and 

  

	 	•	 	 If you are currently enrolled and participating in the Company’s medical/dental/vision benefits, your
coverage will extend until the end of the month that is [NINE (9) MONTHS FOLLOWING YOUR DATE OF TERMINATION/ RESIGNATION IF TERMINATION WITHOUT CAUSE OR RESIGNATION FOR GOOD REASON; TWELVE (12) MONTHS FOLLOWING YOUR DATE OF TERMINATION IF
TERMINATION/RESIGNATION FOLLOWING A CHANGE OF CONTROL]. Thereafter, you will be able to continue as a member of the Company’s Group Health Plans at your expense in accordance with the terms of those plans, as well as COBRA, for the legally
required benefit continuation period. You will be receiving a separate letter explaining your rights and responsibilities with regard to electing your COBRA benefits. 

Within thirty (30) days after you return the signed and dated Agreement, provided you do not revoke it under
Section 22(c), you will begin receiving the salary continuation benefit, provided you did not resign prior to your anticipated Separation Date. 
  

	4.	 W-2s. 

The Company will issue an IRS Form W-2 to you in connection with payments described in
Section 3. 
  

	5.	 How To Enter Into This Agreement. 

In order to enter into this Agreement, you must take the following steps: 

 

	 	a.	 You must sign and date the Agreement. Signing and dating the Agreement is how you “Execute” the
Agreement. 

  

	 	b.	 You must return the Executed Agreement to me before [LAST DATE TO ACCEPT
(TWENTY-ONE (21) CALENDAR DAYS FOLLOWING RECEIPT)], (unless such period is extended in writing by the Company). If I do not receive the signed and dated Agreement by that date, the offer will be deemed
withdrawn, this Agreement will not take effect and you will not receive the pay and benefits described in Section 3. 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

	 	c.	 You must comply with the terms and conditions of this Agreement. 

 

	6.	 Your Acknowledgments. 

By entering into this Agreement, you are agreeing: 
  

	 	•	 	 The pay and benefits in Section 3 are more than any money or benefits that you are otherwise promised or
entitled to receive under any policy, plan, handbook or practice of the Company or any prior offer letter, agreement or understanding between the Company and you. 

 

	 	•	 	 After your employment ends, except as provided for in this Agreement (and without impacting any accrued vested
benefits under any applicable tax-qualified retirement or other benefit plans of the Company), you will no longer participate or accrue service credit of any kind in any employee benefits plan of the Company
or any of its affiliates. 

  

	 	•	 	 Your obligations under your signed Letter of Employment Offer and Terms with the Company (“Offer
Letter”) (a copy of which is attached) and the Employee Non-Disclosure, Invention Assignment and Restrictive Covenant Agreement (“NDA”) executed between you and the Company (also attached),
shall remain in full force and effect and you acknowledge and re-affirm those obligations. 

  

	 	•	 	 As long as the Company satisfies its obligation under the Agreement, it will not owe you anything except for
the items set forth in Section 2, which you will receive regardless of whether you Execute this Agreement. 

  

	7.	 YOU ARE RELEASING AND WAIVING CLAIMS 

While it is very important that you read this entire Agreement carefully, it is especially important that you read
this Section carefully, because it lists important rights you are giving up if you decide to enter into this Agreement. 

Who And What Does The Release Cover? 

What Are You Giving Up? It is the Company’s position that you have no legitimate basis
for bringing a legal action against it. You may agree or believe otherwise or simply not know. However, if you Execute this Agreement, you will, except for certain exceptions described in Section 11, give up your ability to bring a legal
action against the Company and others, including, but not limited to its affiliates. More specifically, by Executing this Agreement, you will give up any right you may have to bring various types of “Claims,” which means possible lawsuits,
claims, demands and causes of action of any kind (based on any legal or equitable 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 
theory, whether contractual, common-law, statutory, federal, state, local or otherwise), whether known or unknown, by reason of any act or omission up to
and including the date on which you Execute this Agreement. You are also giving up potential Claims arising under any contract or implied contract, including but not limited to your Employment Offer and Terms letter or any handbook, tort law or
public policy having any bearing on your employment or the termination of your employment, such as Claims for wrongful discharge, discrimination, hostile work environment, breach of contract, tortious interference, harassment, bullying, infliction
of emotional distress, defamation, back pay, vacation pay, sick pay, wage, commission or bonus payment, equity grants, stock options, restricted stock option payments, payments under any bonus or incentive plan, attorneys’ fees, costs and
future wage loss. This Agreement includes a release of your right to assert a Claim of discrimination on the basis of age, sex, race, religion, national origin, marital status, sexual orientation, gender identity, gender expression, ancestry,
parental status, handicap, disability, military status, veteran status, harassment, retaliation or attainment of benefit plan rights. However, as described in Section 11, this Agreement does not and cannot prevent you from asserting your right
to bring a claim against the Company and Releasees, as defined below, before the Equal Employment Opportunity Commission or other agencies enforcing non-discrimination laws or the National Labor Relations
Board. 
 Whose Possible Claims Are You Giving Up? You are waiving Claims that you may otherwise
be able to bring. You are not only agreeing that you will not personally bring these Claims in the future, but that no one else will bring them in your place, such as your heirs and executors, and your dependents, legal representatives and assigns.
Together, you and these groups of individuals are referred to in the Agreement as“Releasors.” 
 Who Are You
Releasing From Possible Claims? You are not only waiving Claims that you and the Releasors may otherwise be able to bring against the Company, but also Claims that could be brought against “Releasees,” which means the
Company and all of their past, present and future: 
  

	 	•	 	 shareholders 

  

	 	•	 	 officers, directors, employees, attorneys and agents 

 

	 	•	 	 subsidiaries, divisions and affiliated and related entities 

 

	 	•	 	 employee benefit and pension plans or funds 

 

	 	•	 	 successors and assigns 

 

	 	•	 	 trustees, fiduciaries and administrators 

Possible Claims You May Not Know. It is possible that you may have a Claim that you do not know exists. By entering
into this Agreement, you are giving up all Claims that you ever had including Claims arising out of your employment or the termination of your employment. Even if Claims exist that you do not know about, you are giving them up. 

What Types of Claims Are You Giving Up? In exchange for the pay and benefits in Section 3, you (on behalf of
yourself and the Releasors) forever release and discharge the Company and all of the Releasees from any and all Claims including Claims arising under the following laws (including amendments to these laws): 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 Federal Laws, such as: 
  

	 	•	 	 The Age Discrimination in Employment Act; 

 

	 	•	 	 The Older Workers Benefit Protection Act; 

 

	 	•	 	 Title VII of the Civil Rights of 1964; 

 

	 	•	 	 Sections 1981 through 1988 of Title 42 of the United StatesCode; 

 

	 	•	 	 The Civil Rights Act of 1991; 

 

	 	•	 	 The Equal Pay Act; 

  

	 	•	 	 The Americans with Disabilities Act; 

 

	 	•	 	 The Rehabilitation Act; 

 

	 	•	 	 The Employee Retirement Income SecurityAct; 

 

	 	•	 	 The Worker Adjustment and Retraining Notification Act; 

 

	 	•	 	 The National Labor Relations Act; 

 

	 	•	 	 The Fair Credit Reporting Act; 

 

	 	•	 	 The Occupational Safety and Health Act; 

 

	 	•	 	 The Uniformed Services Employment and Reemployment Act; 

 

	 	•	 	 The Employee Polygraph Protection Act; 

 

	 	•	 	 The Immigration Reform Control Act; 

 

	 	•	 	 The Family and Medical Leave Act; 

 

	 	•	 	 The Genetic Information Nondiscrimination Act; 

 

	 	•	 	 The Federal False Claims Act; 

 

	 	•	 	 The Patient Protection and Affordable Care Act; 

 

	 	•	 	 The Consolidated Omnibus Budget Reconciliation Act; and 

 

	 	•	 	 The Lilly Ledbetter Fair Pay Act. 

State and Municipal Laws, such as: 
  

	 	•	 	 The New York State Human Rights Law; the New York State Executive Law; the New York State Civil Rights Law;
the New York State Whistleblower Law; the New York State Legal Recreational Activities Law; the retaliation provisions of the New York State Workers’ Compensation Law; the New York Labor Law; the New York State Worker Adjustment and Retraining
Notification Act; the New York State False Claims Act; New York State Wage and Hour Laws; the New York State Equal Pay Law; the New York State Rights of Persons with Disabilities Law; the New York State Nondiscrimination Against Genetic Disorders
Law; the New York State Smokers’ Rights Law; the New York AIDS Testing Confidentiality Act; the New York Genetic Testing Confidentiality Law; the New York Discrimination by Employment Agencies Law; the New York Bone Marrow Leave Law; the New
York Adoptive Parents Child Care Leave Law; the New York City Human Rights Law; the New York City Administrative Code; the New York City Paid Sick Leave Law; and the New York City Charter; and 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

	 	•	 	 [IF EMPLOYEE WAS EVER EMPLOYED IN NJ] The New Jersey Law Against Discrimination; the New Jersey Discrimination
in Wages Law; the New Jersey Security and Financial Empowerment Act; the New Jersey Temporary Disability Benefits and Family Leave Insurance Law; the New Jersey Domestic Partnership Act; the New Jersey Conscientious Employee Protection Act; the New
Jersey Family Leave Act; the New Jersey Wage Payment Act; the New Jersey Equal Pay Law; the New Jersey Occupational Safety and Health Law; the New Jersey False Claims Act; the New Jersey Smokers’ Rights Law; the New Jersey Genetic Privacy Act;
the New Jersey Fair Credit Reporting Act; the New Jersey Emergency Responder Leave Law; the New Jersey Millville Dallas Airmotive Plant Job Loss Notification Act (a/k/a the New Jersey WARN Act); and the retaliation provisions of the New Jersey
Workers’ Compensation Law; and 

  

	 	•	 	 [IF EMPLOYEE WAS EVER EMPLOYED IN CA] The California Fair Employment and Housing Act, as amended; the
California Constitution, as amended; the California Labor Code, as amended; and all rights under Section 1542 of the California Civil Code, which states, “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR
SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.” You acknowledge that you may later discover claims or facts in
addition to or different from those which you now know or believe to exist with regards to the subject matter of this Agreement, and which, if known or suspected at the time of executing this Agreement, may have materially affected its terms.
Nevertheless, you waive any and all Claims that might arise as a result of such different or additional claims or facts; and 

  

	 	•	 	 [IF EMPLOYEE WAS EVER EMPLOYED IN NC] The North Carolina Employment Practices Act; the Retaliatory Employment
Discrimination Act; the Persons with Disabilities Protection, Discrimination Against Persons with Sickle Cell Trait; Discrimination Based Upon Genetic Testing and Information; Discrimination Based Upon Use of Lawful Products; Discrimination Based
Upon AIDS or HIV Status; Hazardous Chemicals Right to Know Act; Jury Service Discrimination; Military Service Discrimination; and all of their respective implementing regulations; and 

 

	 	•	 	 [IF EMPLOYEE WAS EVER EMPLOYED IN MA] The Massachusetts Fair Employment Practices Law; the Massachusetts Civil
Rights Act; the Massachusetts Equal Rights Act; the Minimum Fair Wage Act; the Massachusetts Plant Closing Law; the Massachusetts Equal Pay Act; the Massachusetts Parental Leave Act; the Massachusetts Sexual Harassment Statute; and all of their
respective implementing regulations. By signing this letter agreement, you are acknowledging that this waiver includes any future claims against the Company under Mass. Gen. Laws ch. 149, § 148—the Massachusetts Wage Act. These claims
include, but are not limited to, failure to pay earned wages, failure to pay overtime, failure to pay earned commissions, failure to timely pay wages, failure to pay accrued vacation or holiday pay, failure to furnish appropriate pay stubs, claims
for improper wage deductions, and claims for failing to provide proper check-cashing facilities. 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 You Are Giving Up Potential Remedies and Relief. You are waiving any
relief that may be available to you (such as money damages, equity grants, benefits, attorneys’ fees, and equitable relief such as reinstatement) under any of the waived Claims, except as provided in Section 11. 

This Release Is Extremely Broad. This release is meant to be as broad as legally permissible and applies to both
employment-related and non-employment-related Claims up to the time that you execute this Agreement. This release includes a waiver of jury trials and non-jury trials.
This Agreement does not release or waive Claims or rights that, as a matter of law, cannot be waived, which include, but are not necessarily limited to, the exceptions to your release of claims or covenant not to sue referenced in Section 11.

  

	8.	 YOU ARE AGREEING NOT TO SUE 

Except as provided in Section 11, you agree not to sue or otherwise bring any legal action against the Company or any of
the Releasees ever for any Claim released in Section 6 arising before you Execute this Agreement. You are not only waiving any right you may have to proceed individually, but also as a member of a class or collective action. You waive any and
all rights you may have had to receive notice of any class or collective action against Releases for claims arising before you Execute this Agreement. In the event that you receive notice of a class or collective action against Releasees for claims
arising before you Execute this Agreement, you must “opt out” of and may not “opt in” to such action. You are also giving up any right you may have to recover any relief, including money damages, from the Releasees as a member of
a class or collective action. 
  

	9.	 Representations Under The FMLA (leave law) And FLSA (wage and hourlaw). 

You represent that you are not aware of any facts that might justify a Claim by you against the Company for any violation of
the Family and Medical Leave Act (“FMLA”). You also represent that you have received all wages for all work you performed and any commissions, bonuses, stock options, restricted stock option payments, overtime compensation and FMLA leave
to which you may have been entitled, and that you are not aware of any facts constituting a violation by the Company or Releasees of any violation of the Fair Labor Standards Act or any other federal, state or municipal laws. 

 

	10.	 You Have Not Already Filed An Action. 

You represent that you have not sued or otherwise filed any actions (or participated in any actions) of any kind against the
Company or Releasees in any court or before any administrative or investigative body or agency. The Company is relying on this assurance in entering into this Agreement. 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

	11.	 Exceptions To Your Release Of Claims And Covenant Not To Sue 

In Sections 7 and 8, you are releasing Claims and agreeing not to sue, but there are exceptions to those commitments.
Specifically, nothing in this Agreement prevents you from bringing a legal action or otherwise taking steps to: 
  

	 	•	 	 Enforce the terms of this Agreement; or 

 

	 	•	 	 Challenge the validity of this Agreement; or 

 

	 	•	 	 Make any disclosure of information required by law; or 

 

	 	•	 	 Provide information to, testify before or otherwise assist in any investigation or proceeding brought by, any
regulatory or law enforcement agency or legislative body, any self-regulatory organization, or the Company; or 

  

	 	•	 	 Provide truthful testimony in any forum; or 

 

	 	•	 	 Cooperate fully and provide information as requested in any investigation by a governmental agency or
commission; or 

  

	 	•	 	 File a charge or complaint with the Equal Employment Opportunity Commission, the National Labor Relations
Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (“Government Agencies”);or 

 

	 	•	 	 File a lawsuit or other action to pursue Claims that arise after you Execute this Agreement.

 For purposes of clarity, this Agreement does not limit your ability to communicate with any Government
Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. This Agreement does not limit your right to
receive an award for information provided to any Government Agencies. 
  

	12.	 Your Continuing Obligations. 

You acknowledge and re-affirm your continuing obligations pursuant to the Offer Letter
and the NDA executed between you and the Company, including your confidentiality obligations under Section 2 of the NDA and any restrictions under Sections 4 and 5 of the NDA. 

Pursuant to the Defend Trade Secrets Act of 2016, you acknowledge and understand that you will not be held criminally or
civilly liable under any federal or state trade secret law for the disclosure of the trade secrets of the Company or any of its affiliates that is made by you (i) in confidence to a federal, state, or local government official, either directly
or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law, or (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

	13.	 Return Of Property. 

As of your Separation Date, you agree that you have returned to the Company all property belonging to the Company including,
but not limited to, electronic devices, equipment, access cards, and paper and electronic documents obtained in the course of your employment. 
  

	14.	 Prior Disclosures. 

You acknowledge that, prior to the termination of your employment with the Company, you disclosed to the Company, in accordance
with applicable policies and procedures, any and all information relevant to any investigation of the Company’s business practices conducted by any governmental agency or to any existing, threatened or anticipated litigation involving the
Company, whether administrative, civil or criminal in nature, and that you are otherwise unaware of any wrongdoing committed by any current or former employee of the Company that has not been disclosed. Nothing in this Agreement shall prohibit or
restrict you or the Company from (1) making any disclosure of information required by law; (2) providing information to, or testifying or otherwise assisting in any investigation or proceeding brought by any federal or state regulatory or
law enforcement agency or legislative body, any self-regulatory organization, or with respect to any internal investigation by the Company or its affiliates; or (3) testifying, participating in or otherwise assisting in a proceeding relating to
an alleged violation of the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, any federal, state or municipal law relating to fraud, or any rule or regulation of any self-regulatory organization. 

 

	15.	 Non-Disparagement 

You agree that you will not, through any medium including, but not limited to, the press, Internet or any other form of
communication, disparage, defame, or otherwise damage or assail the reputation, integrity or professionalism of the Company or the Releasees. Nothing in this Section 15 is intended to restrict or impede your participation in proceedings or
investigations brought by or before the EEOC, NLRB, or other federal, state or local government agencies, or otherwise exercising protected rights to the extent that such rights cannot be waived by agreement, including Section 7 rights under
the National Labor Relations Act. 
  

	16.	 The Company’s Remedies For Breach. 

If you breach any section of this Agreement, including without limitation, Section 7, 8, or 15 or otherwise seek to bring
a Claim given up under this Agreement, the Company will be entitled to all relief legally available to it including equitable relief such as injunctions, and the Company will not be required to post a bond. 

 

	17.	 Governing Law. 

This Agreement is governed by New York law, without regard to conflicts of laws principles. 

 

	18.	 Successors And Assigns. 

This Agreement is binding on the Parties and their heirs, executors, successors and assigns. 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

	19.	 Severability And Construction. 

If a court with jurisdiction to consider this Agreement determines that any provision is illegal, void or unenforceable, that
provision will be modified or substituted to be generally consistent with the original intent or invalid, if necessary. However, the rest of the Agreement will remain in full force and effect. A court with jurisdiction to consider this Agreement may
modify invalid provisions if necessary to achieve the intent of the Parties. 
  

	20.	 No Admission. 

By entering into this Agreement, neither you nor the Company admits wrongdoing of any kind. 

 

	21.	 Do Not Rely On Verbal Statements. 

 

	 	•	 	 This Agreement sets forth the complete understanding between the Parties. 

 

	 	•	 	 This Agreement may not be changed orally. 

 

	 	•	 	 This Agreement constitutes and contains the complete understanding of the Parties with regard to the end of your
employment, and supersedes and replaces all prior oral and written agreements and promises between the Parties, except that, as set forth in Section 6, your restrictive covenant obligations remain in full force and effect.

  

	 	•	 	 Neither the Company nor any representative (nor any representative of any other company affiliated with the
Company), has made any promises to you other than as written in this Agreement. All future promises and agreements must be in writing and signed by both Parties. 

 

	22.	 Your Opportunity To Review and Revoke. 

 

	 	a.	 Twenty-One Day Review Period. You have twenty-one (21)calendar days from the day you receive this Agreement to consider the terms of this Agreement, sign it and return it to [Contact Name], 320 West 37th Street, 6th Floor, New York, NY 10018. Your opportunity to accept the terms of this Agreement will expire at the conclusion of the twenty-one
(21) calendar day period if you do not accept those terms before time expires. That means that your opportunity to accept the terms of this Agreement will expire on [LAST DATE TO ACCEPT]. You may sign the Agreement in fewer than twenty-one (21) calendar days, if you wish to do so. If you elect to do so, you acknowledge that you have done so voluntarily. Your signature below indicates that you are entering into this Agreement
freely, knowingly and voluntarily, with full understanding of its terms. 

  

	 	b.	 Talk To A Lawyer. During the twenty-one (21) calendar-day review period, and before executing this Agreement, the Company advises you to consult with an attorney, at your own expense, regarding the terms of this Agreement.

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

	 	c.	 Seven Days to Change Your Mind. You have seven (7) calendar days
from the date of signing this Agreement to revoke the Agreement by expressing a desire to do so in writing addressed to the Head of Human Resources of the Company or their designee, [Address], email address:
[Contact.Name]@            .com. 

  

	23.	 We Want To Make Absolutely Certain That You Understand This Agreement.  

You acknowledge and agree that: 
  

	 	•	 	 You have carefully read this Agreement in its entirety; 

 

	 	•	 	 You have had an opportunity to consider the terms of this Agreement for at least twenty-one (21) calendar days; 

  

	 	•	 	 You understand that the Company urges you to consult with an attorney of your choosing, at your expense,
regarding this Agreement; 

  

	 	•	 	 You have the opportunity to discuss this Agreement with a lawyer of your choosing, and agree that you had a
reasonable opportunity to do so, and he or she has answered to your satisfaction any questions you asked with regard to the meaning and significance of any of the provisions of this Agreement; 

 

	 	•	 	 You fully understand the significance of all of the terms and conditions of this Agreement; and

  

	 	•	 	 You are Executing this Agreement voluntarily and of your own free will and agree to all the terms and
conditions contained in this Agreement. 

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com	  	

 

 
  

 YOU AGREE THAT ANY MODIFICATIONS, MATERIAL OR OTHERWISE, MADE TO THIS AGREEMENT DO NOT
RESTART, EXTEND OR AFFECT IN ANY MANNER THE ORIGINAL SEVEN (7) CALENDAR DAY REVIEW PERIOD DESCRIBED ABOVE. 
  

									
	
                     
    
	 		 	
                     
                

	DERMAVANT SCIENCES, INC.	 	        	 	[NAME]
					
	By:	 	
                     
            
	 	        	 		 	
	Dated:	 	
                     
    
	 		 	Dated:	 	
                     
    

  

  
  

					
	DB1/ 100340191.3	  	Dermavant Sciences, Inc. • dermavant.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]